Acamar Films EIS – pre-emption rights

Archived article

Archived article: please remember tax and investment rules and circumstances can change over time. This article reflects our views at the time of publication.

Acamar Films EIS has recently sent a shareholder update. It included the announcement of an offer only opened to existing shareholders. If you're interested, it's a short deadline – a response is required by next Wednesday, 27 February.

Complete the simple details below to get information on next steps

What is the offer?

Existing shareholders benefit from pre-emption rights. You can buy new shares in a new share class (‘B Investor Premium NV’) with no voting rights. To reflect this the cost per share is £4.50 (10% lower than the current share price of £5).

Importantly, these shares are eligible for EIS. Acamar had previously reached the maximum a company can raise under EIS. However, it has now been granted Knowledge Intensive Company status by HMRC, so it can raise additional funds with the benefit of EIS relief.

How much could you subscribe?

You are entitled to 0.112 NV shares for every existing share you hold. This works out roughly as 11% of your existing shareholding.

So, for instance, if you hold 4,000 shares, you would be entitled to 448 NV shares, at a cost of £2,016. 

You might be able to subscribe more, depending on how many existing shareholders take up this offer. The maximum Acamar Films EIS can raise overall is £4.5 million. 

Action required by Wednesday 27 February 2019

Please complete the simple form at the top of this page to request that we get in touch to confirm your entitlement and discuss next steps. Please note, this is not advice or a personal recommendation to invest.

If we don’t hear from you by 27 February 2019 your rights will lapse. 

Before proceeding, please make sure you download and read carefully:

Wealth Club aims to make it easier for experienced investors to find information on – and apply for – tax-efficient investments. You should base your investment decision on the provider's documents and ensure you have read and fully understand them before investing. This review is a marketing communication. It is not advice or a personal or research recommendation to buy the investment mentioned. It does not satisfy legal requirements promoting investment research independence and is thus not subject to prohibitions on dealing ahead of its dissemination.